Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Exp Hematol. 2010 Sep 18;39(1):77–86.e1-5. doi: 10.1016/j.exphem.2010.09.003

Fig. 1.

Fig. 1

The transforming domain of AF9 associates with other MLL fusion partners and key transcriptional regulators (EAP) A) Silver stain of proteins co-purifying with AF9 and the control fragment from M1-AF9 and M1-control cell lysate, respectively. Both lanes were subjected to tandem mass spectrometry. A subset of proteins identified specifically associating with AF9 are listed to the right. B) Western blot confirmation of interactions identified by MS. The asterisk indicates the band corresponding to LAF4. Antibodies used for detection are indicated below blots. Input represents 1% of total lysate. C) Western blot for EAP in M1-AF9 and M1-control cells after FLAG IP with Benzonase treatment. D) Western blot after immunoprecipitations performed on 293 cells transfected with control, a FLAG-HA-tagged N-terminal MLL fragment encoding residues 1116–1397 of MLL (MLL1116–1397) with HA-Dot1L, or FLAG-MLL-AF9 with HA-tagged Dot1L expression vectors shows that that CDK9 and Dot1 specifically interact with MLL-AF9. Antibodies used for detection are indicated below the blots. HA detects HA-FLAG-MLL1116–1397 (second panel) and HA-Dot1L (third panel). The asterisk indicates the band corresponding to F-MLL-AF9. Approximate molecular weights are indicated to the right of the bands. Input represents 5% of total lysate.